Watson Takes Over Eden Biodesign
Reportedly, Eden, which will be a part of global brands division of Watson, will maintain its established contract services model, while providing the company with biopharmaceutical development and
Novartis has entered a collaboration with Chai Discovery to advance the use of AI in the identification of therapeutic antibodies.